BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 9, 2026
Home » Blogs » BioWorld MedTech Perspectives » Alas, poor Berwick! His nomination bid appears headed for an early grave

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / CMS / Medicare

Alas, poor Berwick! His nomination bid appears headed for an early grave

March 10, 2011
By Holland Johnson
Obama

The recess appointment of Donald Berwick, MD, to the administrator’s position at the Centers for Medicare & Medicaid Services (CMS) last July roiled many members of Congress, and a recent Senate letter to the Obama administration expressing disfavor for Berwick’s continued presence at CMS may have finally lain to rest any chance that he had of a successful confirmation hearing.

The letter, whose principal authors include Sen. Mike Enzi (R-Wyoming), the ranking GOP member of the Senate Health, Education, Labor and Pensions Committee, and Orrin Hatch (R-Utah), the ranking GOP member of the Senate Finance Committee, cite Berwick’s “past record of controversial statements and general lack of experience managing an organization as large and complex as CMS,” which the authors said “should disqualify him being confirmed as the CMS administrator.” The signers also expressed their ire that President Obama had pledged “a new era of transparency in our government,” but the recess appointment of Berwick and the back-room drafting of the Patient Protection and Affordable Care Act of 2010 “both contradict your pledge,” the authors say. A total of 42 Republican senators signed on to the letter.

It appears that Senate Democrats are beginning to think Berwick’s bid to retain the job is in serious jeopardy, given that confirmation would require 60 votes to avert a filibuster, a total Berwick’s supporters largely do not see as likely.

Berwick’s principal deputy, Marilyn Tavenner, appears to be a likely candidate to succeed him, and with her private- and public-sector healthcare administrative experience, lawmakers of both parties have indicated that she could probably be confirmed.

The recess appointment allows Berwick to serve to the end of this year.  The president has nominated Berwick three times, most recently in January. It remains unclear whether President Obama will nominate him for a fourth time, though White House spokesman Reid Cherlin said the administration would not withdraw Berwick’s nomination. 

“The president nominated Don Berwick because he’s far and away the best person for the job, and he’s already doing stellar work at CMS: Saving taxpayer dollars by cracking down on fraud and implementing delivery-system reforms that will save billions in excess costs and save millions of lives,” Cherlin said in a statement.

So what do you think, does Berwick have a legitimate chance at nomination, or is he just whistling past the graveyard?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 8, 2026.
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • 3D illustration of antibodies

    Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

    BioWorld Science
    Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing